Inner Cosmos is a neuromodulation company that has created the world’s first Digital Pill for patients who are resistant to pharmaceutical treatments of depression and are seeking a clinically proven solution.

Depression is the leading cause of disability worldwide with more than 21 million people in the U.S. under treatment, but for 30% of patients current drugs offer no relief. One FDA-approved solution, Transcranial Magnetic Stimulation (TMS), is highly effective but requires 30 continuous days of in-hospital treatment every 6 to 12 months, which is not logistically feasible for many patients.

The Digital Pill is based on similar proven technology but is in a miniaturized, implanted form that solves three problems: access, feedback, and peace of mind in knowing that the device is there when needed. It delivers precise pulses that stimulate specific areas of the brain to treat depression without the side effects that occur with drug treatment. Psychiatrists use an AI-based “mood graph” generated by the device to make small adjustments to the stimulations to continuously improve depression treatments. It is minimally embedded and the most clinically advanced technology in the brain computer interface space in development.

Inner Cosmos expects to complete its safety study with this Seed investment and plans to raise its Series A round to initiate a pivotal study in 2026 to get its anticipated therapy approved by the FDA and on the market when these studies are complete.

Register now to watch this webinar with Inner Cosmos co-founder and CEO, Meron Gribetz to learn how the Digital Pill is the first implanted treatment for depression to be tested in a clinical setting in 20 years.